血脂康对急性冠脉综合征患者炎症反应的影响  

Effect of Xuezhikang on the Inflammation Response in Acute Coronary Syndrome

作　　者：陈雯[1] 吴锦鸿[1] 许国根[1] 

机构地区：[1]杭州市第一人民医院急诊科,杭州310006

出　　处：《浙江中西医结合杂志》2007年第8期471-472,共2页Zhejiang Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:观察血脂康对急性冠脉综合征(ACS)患者炎症反应的影响。方法:随机选择ACS患者67例和对照组70例,检测血清CRP和IL-6。67例ACS患者随机分为血脂康(治疗组)34例,阿托伐他汀治疗(对照组)33例,进行治疗前后血清CRP和IL-6水平进行对比分析。结果:①ACS组患者CRP和IL-6水平显著升高,与对照组比较,差异有显著性意义,P<0.01。②血脂康和阿托伐他汀均可明显降低ACS患者血清CRP和IL-6水平,与治疗前比较,P均<0.01。结论:ACS患者CRP和IL-6水平均有明显升高,存在明显的炎症反应。血脂康治疗能有效抑制此类炎症反应。Objective：To obverse the curative effect of Xuezhikang on the inflammation response in acute coronary syndrome （ACS）. Methods ：67 cases of ACS and 70 cases as the contrast group were randomly chosen and the levels of serum CRP and IL-6 were detected respectively. 67 cases of ACS were randomly divided into the Xuezhikang group （34 cases ） and the Atorvastatin group （33 cases）. The levels of serum CRP and IL-6 before and after therapy were compared and analyzed. Results：（1）The levels of CRP and IL-6 in the ACS were obviously improved than those in the contrast group. The difference has significant meaning （ P 〈 0.01 ）. （2）Therapy by Xuezhikang and Atorvastatin could decrease the levels of CRP and IL-6 in the cases of CAS with P 〈0.01 compared with that before therapy. Conclusion：The levels of CRP and IL-6 in the cases of ACS obviously improve, which shows cases with ACS have inflammation response. Therapy by Xuezhikang has good effect on restraining the inflammation response in ACS.

关 键 词：急性冠脉综合征 炎症反应 血脂康 C反应蛋白 白介素-6 

分 类 号：R259[医药卫生—中西医结合]